The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 25, 2021
Filed:
Jan. 25, 2016
Applicant:
Cellectis, Paris, FR;
Inventors:
Julianne Smith, New York, NY (US);
Julien Valton, New York, NY (US);
Alexandre Juillerat, New York, NY (US);
Philippe Duchateau, Draveil, FR;
Barbra Johnson Sasu, San Francisco, CA (US);
Arvind Rajpal, San Francisco, CA (US);
Assignee:
Cellectis, Paris, FR;
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); C07K 16/28 (2006.01); C07K 14/725 (2006.01); C07K 16/30 (2006.01); C12N 5/00 (2006.01); C12N 5/0783 (2010.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 14/705 (2006.01); C07K 14/735 (2006.01); G01N 15/10 (2006.01); G01N 15/14 (2006.01); G01N 15/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2866 (2013.01); A61K 35/17 (2013.01); A61K 39/0011 (2013.01); A61K 39/001176 (2018.08); A61K 39/39558 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70535 (2013.01); C07K 14/70578 (2013.01); C07K 16/2803 (2013.01); C07K 16/2887 (2013.01); C07K 16/3061 (2013.01); C12N 5/0093 (2013.01); C12N 5/0636 (2013.01); C12N 5/0638 (2013.01); G01N 15/1031 (2013.01); G01N 15/14 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/6056 (2013.01); A61K 2039/64 (2013.01); C07K 2317/24 (2013.01); C07K 2317/53 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2319/00 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C12N 2510/00 (2013.01); G01N 2015/008 (2013.01); G01N 2015/1006 (2013.01); G01N 2015/1081 (2013.01); G01N 2015/149 (2013.01);
Abstract
The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward CLL1 positive cells. The engineered immune cells endowed with such CARs are particularly suited for immunotherapy for treating cancer, in particular leukemia.